FDA Updates Draft Guidance on Promotional Communications of Prescription Biologics and Biosimilars
Big Molecule Watch
MAY 3, 2024
The guidance remains in draft form and, as with any FDA guidance document, it is not legally binding and, when final, will reflect FDA’s “current thinking” on this topic. The 60-day comment period for this revised draft guidance ends on 6/24/2024. Instructions for submitting comments to this guidance can be found here.
Let's personalize your content